Immunization Safety Review: Vaccines and Autism (2004)

Chapter: Appendix B: Public Meeting Agenda February 9, 2004

Previous Chapter: Appendix A: Committee Recommendations andConclusions from Previous Reports
Suggested Citation: "Appendix B: Public Meeting Agenda February 9, 2004." Institute of Medicine. 2004. Immunization Safety Review: Vaccines and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10997.

Appendix B
Public Meeting Agenda February 9, 2004

Immunization Safety Review Vaccines and Autism

National Academy of Sciences Building

Auditorium, 2100 C Street, NW

Washington, DC

8:00–8:15 am

Welcome and Opening Remarks

Marie McCormick, M.D., Sc.D., Committee Chair

8:15–8:30 am

Congressional Speakers

Congressman Dave Weldon,

U.S. House of Representatives

8:30–9:30 am

Etiologic Factors and Pathogenesis of Autism: Evidence from Clinical Studies and Animal Models

Mady Hornig, M.D., Associate Professor,

Columbia University Mailman School of Public Health

Suggested Citation: "Appendix B: Public Meeting Agenda February 9, 2004." Institute of Medicine. 2004. Immunization Safety Review: Vaccines and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10997.

9:30–10:00 am

Association of Autistic Spectrum Disorder and MMR Vaccine: A Systematic Review of Current Epidemiological Evidence

Kumanan Wilson, M.D., M.Sc., Division of Clinical Decision Making and Health Care, Toronto General Research Institute, Canada

10:00–10:30 am

Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects

Frank DeStefano, M.D., Centers for Disease Control and Prevention

10:30–10:45 am

Break

10:45–11:15 am

Exposure to Thimerosal-Containing Vaccines in U.K. Children and Autism

Dr. Elizabeth Miller, Head, Immunisation Division, Public Health Laboratory Service, Communicable Disease Surveillance Centre, London

11:15–11:45 am

Vaccine Safety Datalink Study: Autism Outcome

Robert L. Davis, M.D., M.P.H., University of Washington Group Health, Cooperative Departments of Pediatrics Center for Health Studies and Epidemiology

11:45–12:15 pm

Study of the Association Between Thimerosal-Containing Vaccine and Autism in Denmark

Anders Peter Hviid, M.Sc., Department of Epidemiology Research, State Serum Institute, Copenhagen, Denmark

12:15–12:45 pm

Autism and Thimerosal-Containing Vaccines: Analysis of the Vaccine Adverse Events Reporting System (VAERS)

Mark R. Geier, M.D., Ph.D., President, The Genetic Centers of America

David Geier, President of MedCon

12:45–1:45 pm

Lunch

Suggested Citation: "Appendix B: Public Meeting Agenda February 9, 2004." Institute of Medicine. 2004. Immunization Safety Review: Vaccines and Autism. Washington, DC: The National Academies Press. doi: 10.17226/10997.

1:45–2:15 pm

A Toxicologist’s View of Thimerosal and Autism

H. Vasken Aposhian, Ph.D., Professor, Molecular and Cellular Biology, University of Arizona

2:15–2:45 pm

Relation of Neurotoxic Effects of Thimerosal to Autism

David Baskin, M.D., Professor of Neurosurgery and Anesthesiology, Baylor College of Medicine

2:45–3:15 pm

Thimerosal Exposure from Vaccines and Ethylmercury Accumulation in Nonhuman Primates

Dr. Polly Sager, Assistant Director for International Research, National Institute of Allergy and Infectious Diseases

3:15–3:30 pm

Break

3:30–4:00 pm

Reduced Levels of Mercury in First Baby Haircuts of Autistic Children

Boyd Haley, Ph.D., Chairman and Professor, Department of Chemistry, University of Kentucky

4:00–4:30 pm

A Case-Control Study of Mercury Burden in Children with Autistic Disorders and Measles Virus Genomic RNA in Cerebrospinal Fluid in Children with Regressive Autism

Jeff Bradstreet, M.D., FAAFP, Adjunct Professor, Neurosciences, Stetson University, Director of Clinical Programs, International Child Development Resource Center, Florida

4:30–5:00 pm

Autism, Vaccines, and Immune Reactions

Vijendra K. Singh, Ph.D., Research Associate Professor, Utah State University

5:00–5:30 pm

Public Comment Period

5:30 pm

Adjourn

Next Chapter: Appendix C: Thimerosal Content in Licensed Vaccines (Adapted from FDA, 2003, 2004)
Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.